Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Duopharma Biotech Berhad Yönetim
Yönetim kriter kontrolleri 4/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
Leonard bin Abdul Shatar
İcra Kurulu Başkanı
RM 2.5k
Toplam tazminat
CEO maaş yüzdesi | 47.8% |
CEO görev süresi | 16.8yrs |
CEO sahipliği | n/a |
Yönetim ortalama görev süresi | 3.4yrs |
Yönetim Kurulu ortalama görev süresi | 6.6yrs |
Son yönetim güncellemeleri
Recent updates
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005
Aug 27Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018
Apr 04Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price
Feb 17These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively
Oct 21Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005
Aug 18Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Aug 07Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year
Mar 28Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Mar 27We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings
Nov 26Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021
Nov 25Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005
Aug 20Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly
May 22Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend
Apr 13A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Mar 14Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly
Feb 12Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?
Jan 28Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?
Jan 12CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Jun 30 2024 | n/a | n/a | RM 49m |
Mar 31 2024 | n/a | n/a | RM 45m |
Dec 31 2023 | RM 3k | RM 1k | RM 53m |
Sep 30 2023 | n/a | n/a | RM 61m |
Jun 30 2023 | n/a | n/a | RM 69m |
Mar 31 2023 | n/a | n/a | RM 72m |
Dec 31 2022 | RM 2m | RM 1m | RM 70m |
Sep 30 2022 | n/a | n/a | RM 69m |
Jun 30 2022 | n/a | n/a | RM 69m |
Mar 31 2022 | n/a | n/a | RM 68m |
Dec 31 2021 | RM 2m | RM 1m | RM 66m |
Sep 30 2021 | n/a | n/a | RM 66m |
Jun 30 2021 | n/a | n/a | RM 63m |
Mar 31 2021 | n/a | n/a | RM 63m |
Dec 31 2020 | RM 2m | RM 924k | RM 59m |
Sep 30 2020 | n/a | n/a | RM 54m |
Jun 30 2020 | n/a | n/a | RM 55m |
Mar 31 2020 | n/a | n/a | RM 54m |
Dec 31 2019 | RM 2m | RM 882k | RM 55m |
Sep 30 2019 | n/a | n/a | RM 58m |
Jun 30 2019 | n/a | n/a | RM 55m |
Mar 31 2019 | n/a | n/a | RM 51m |
Dec 31 2018 | RM 1m | RM 876k | RM 48m |
Tazminat ve Piyasa: Leonard 'nin toplam tazminatı ($USD 607.91 ), MY pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 202.80K ).
Tazminat ve Kazançlar: Leonard 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Leonard bin Abdul Shatar (59 yo)
16.8yrs
Görev süresi
RM 2,533
Tazminat
Encik Ariff bin Abdul Shatar, also known as Leonard, has been Group Managing Director of Duopharma Biotech Berhad (alternate name Duopharma Biotech Bhd) since December 28, 2017. Encik bin Abdul Shatar serv...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Group MD & Executive Director | 16.8yrs | RM 2.53k | Veri yok | |
Chief Financial Officer | 12.3yrs | Veri yok | 0.000010% MYR 131.8 | |
Chief Legal Officer & Group Company Secretary | 6.8yrs | Veri yok | Veri yok | |
Chief Compliance Officer | 1.3yrs | Veri yok | Veri yok | |
Chief Manufacturing & Sustainability Officer | 2yrs | Veri yok | 0.00030% MYR 4.0k | |
Group Head of Risk Management & Integrity | 1.8yrs | Veri yok | Veri yok | |
Chief Executive Officer of Corporate | 2yrs | Veri yok | Veri yok | |
Chief Executive Officer of Duopharma Consumer Healthcare Sdn. Bhd. | 4.8yrs | Veri yok | Veri yok |
3.4yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: DPHARMA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.4 yıldır).
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
Group MD & Executive Director | 6.8yrs | RM 2.53k | Veri yok | |
Independent Non-Executive Director | less than a year | Veri yok | Veri yok | |
Independent Non-Executive Director | 8.3yrs | RM 130.80k | Veri yok | |
Non Independent Non Executive Director | 6.6yrs | RM 146.40k | 0.0026% MYR 34.7k | |
Independent Non-Executive Director | 6.8yrs | RM 143.80k | Veri yok | |
Independent Non-Executive Director | 5.1yrs | RM 135.40k | Veri yok | |
Independent Non Executive Director | 8.1yrs | RM 143.80k | Veri yok | |
Senior Independent Non-Executive Director | 7.9yrs | RM 141.40k | Veri yok | |
Non-Independent & Non-Executive Chairman | 1.3yrs | RM 76.70k | Veri yok | |
Non Independent & Non Executive Alternate Director | 1.2yrs | Veri yok | Veri yok | |
Non-Independent & Non-Executive Director | less than a year | Veri yok | Veri yok |
6.6yrs
Ortalama Görev Süresi
64yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: DPHARMA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.6 yıldır).